Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls

Hormone and Metabolic Research

Volumn 43, Issue 2, 2011, Pages 141-145

  Cho, L W ^a   Kilpatrick, E S ^a   Keevil, B G ^b   Jayagopal, V ^c   Coady, A M ^d   Rigby, A S ^a   Atkin, S L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c YORK HOSPITAL   (United Kingdom)

^d HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

cardiovascular risk; insulin resistance; ovulation; polycystic ovary syndrome

Indexed keywords

GLUCOSE; INSULIN; PROGESTERONE; TESTOSTERONE;

ADULT; ANOVULATION; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

ADULT; ANOVULATION; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; OVULATION; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 79551610689     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1270450     Document Type: Article

References (37)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004 89 2745-2749
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000 85 2434-2438
3. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998 83 3078-3082
4. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999 84 4006-4011
5. Franks S. Polycystic ovary syndrome. N Engl J Med 1995 333 853-861
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997 18 774-800
7. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006 295 1681-1687
8. Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2009 70 233-237
9. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 2002 87 1560-1562
10. ESHRE/ASRM-Sponsored-PCOS-Consensus-Workshop-Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 81 19-25
11. Greer IA, Cameron IT, Magowan B, Roberts RN, Walker JJ. Problem Based Obstetrics and Gynaecology. Oxford Elsevier Health Sci 2003
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419
13. Gowans EM, Fraser CG. Biological variation of serum and urine creatinine and creatinine clearance: ramifications for interpretation of results and patient care. Ann Clin Biochem 1988 25 259-263
14. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989 27 409-437
15. Forst T, Hohberg C, Pfutzner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009 41 123-131
16. Andersen K, Pedersen BK. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm Metab Res 2008 40 635-639
17. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995 136 2143-2149
18. Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, Chrousos GP, Legro RS. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006 55 1076-1082
19. Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O, Krone W. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res 2010 42 268-273
20. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007 88 401-405
21. Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL, Ho LT. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 2004 19 48-53
22. Munir I, Yen HW, Baruth T, Tarkowski R, Azziz R, Magoffin DA, Jakimiuk AJ. Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab 2005 90 4852-4857
23. Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004 81 361-366
24. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombardi G, Lobo RA. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005 152 389-394
25. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB, Lobo RA. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006 119 356 e351-e356
26. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, Panidis D. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008 69 634-641
27. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002 87 2013-2017
28. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000 52 595-600
29. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007 67 735-742
30. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, Ingadottir G, Crowley WF. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006 91 4842-4848
31. Carmina E. The spectrum of androgen excess disorders. Fertil Steril 2006 85 1582-1585
32. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010 94 2197-2201
33. Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999 71 319-322
34. Carmina E, Longo A, Lobo RA. Does ovarian blood flow distinguish between ovulatory and anovulatory patients with polycystic ovary syndrome? Am J Obstet Gynecol 2003 189 1283-1286
35. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril 2009 91 1332-1335
36. Joseph-Horne R, Mason H, Batty S, White D, Hillier S, Urquhart M, Franks S. Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum Reprod 2002 17 1459-1463
37. Diamanti-Kandarakis E, Piouka A, Livadas S, Piperi C, Katsikis I, Papavassiliou AG, Panidis D. Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 2009 160 847-853